文献速递生殖医学

冻融囊胚移植日血清雌二醇水平高与经皮雌激素人工周期早期流产率增加相关

High serum estradiol levels on the day of frozen blastocyst transfer are associated with increased early miscarriage rates in artificial cycles using transdermal estrogens.
PubMed 文献 · Hum Reprod · 2025-01-01

这项回顾性队列研究分析了2364例接受激素替代治疗冻融囊胚移植(HRT-FBT)并使用经皮雌激素的患者,发现移植日血清雌二醇(E2)≥313 pg/ml与早期流产率升高相关(校正OR 1.5,95%CI 1.06-2.18),但活产率无显著差异。

要点

  • 移植日E2≥313 pg/ml组早期流产风险较122-312 pg/ml组升高(校正OR 1.5,95%CI 1.06-2.18)。
  • E2≥313 pg/ml组与<122 pg/ml组的活产率与参考组相比均无显著差异。
  • 临床妊娠率与新生儿结局在各E2组间无显著差异。

核心结论

  • 移植日E2≥313 pg/ml与早期流产率增加相关,但未显著影响活产率。

研究设计与样本

  • 回顾性队列研究,纳入2019年1月至2022年12月在一所大学医院接受HRT-FBT的2364例患者,每例仅纳入一次。
  • 患者接受单囊胚自体移植,使用经皮雌激素和阴道微粒化黄体酮,移植日晨于单一实验室测血清E2。

主要发现

  • E2分组:<122 pg/ml组590例,122-312 pg/ml组1184例,≥313 pg/ml组590例;总人群中位E2为195.3 pg/ml(122.1-312.8)。
  • 活产率在三组分别为33.7%、31.6%、31.0%;<122 pg/ml组和≥313 pg/ml组 vs 122-312 pg/ml组的校正OR分别为0.9(95%CI 0.72-1.14)和0.9(95%CI 0.69-1.09)。
  • 早期流产率在三组分别为25.5%、24.6%、30.3%;多变量分析显示≥313 pg/ml组 vs 122-312 pg/ml组的校正OR为1.5(95%CI 1.06-2.18)。
  • 临床妊娠率和新生儿结局(出生体重和分娩孕周)在各组间无显著差异。

临床怎么用

  • 作者认为管理FBT日的高血清E2水平可能改善辅助生殖技术结局。
  • 作者建议未来研究应确定HRT-FBT周期的优化E2阈值,并制定考虑个体变异的个性化治疗方案。

局限性

  • 主要局限性为回顾性设计,引入了选择偏倚和混杂偏倚的风险,尽管采用了多变量分析以减轻这些问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Do serum estradiol (E2) levels on the day of frozen blastocyst transfer (FBT) affect pregnancy outcomes in hormonal replacement therapy (HRT) cycles using transdermal estrogens? SUMMARY ANSWER: E2 levels ≥313 pg/ml on the day of FBT are associated with increased early miscarriage rates (EMRs), but do not significantly impact the live birth rate (LBR). WHAT IS KNOWN ALREADY: E2 plays a crucial role in endometrial receptivity and placentation. The effect of serum E2 levels measured around the time of FBT in HRT cycles remains debated, with some studies indicating a negative impact of high E2 levels and others finding no significant difference. Currently, no studies focus exclusively on HRT cycles using transdermal estrogens, which are considered safer regarding thromboembolic complications. STUDY DESIGN, SIZE, DURATION: This retrospective cohort study analyzed 2364 patients undergoing HRT-FBT cycles at a university hospital between January 2019 and December 2022. Each patient was included only once during the study period. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study involved patients undergoing single autologous FBT under HRT with transdermal estrogens and vaginal micronized progesterone. Serum E2 levels were measured in the morning of the FBT at a single laboratory. Primary outcomes included the LBR, with secondary outcomes encompassing clinical pregnancy rates, EMRs, and neonatal outcomes (birth weight and term of delivery). Patients were categorized into three groups based on E2 levels: <25th centile (<122 pg/ml), between 25th and 75th centile (122-312 pg/ml), and >75th centile (≥313 pg/ml), and analyzed using univariate and multivariate logistic regression models. MAIN RESULTS AND THE ROLE OF CHANCE: Of the 2364 patients, 590 were in the '<122 pg/ml' group, 1184 in the '122-312 pg/ml' group, and 590 in the '≥313 pg/ml' group. The median (interquartile range) E2 level in the entire study population was 195.3 pg/ml (122.1-312.8). The LBRs across the E2 level groups were 33.7%, 31.6%, and 31.0%. Crude and adjusted odds ratios (ORs) showed no significant differences in LBR between the '<122 pg/ml' and '≥313 pg/ml' groups compared to the '122-312 pg/ml' reference group (adjusted OR 0.9, 95% CI 0.72-1.14 and 0.9, 95% CI 0.69-1.09, respectively). The EMRs for the groups were 25.5%, 24.6%, and 30.3%, respectively. While crude analysis showed no differences between the groups, the multivariable analysis indicated that the '≥313 pg/ml' group had a significantly higher risk of early miscarriage compared to the reference group (adjusted OR 1.5, 95% CI 1.06-2.18). No significant differences were observed in clinical pregnancy rates or neonatal outcomes. LIMITATIONS, REASONS FOR CAUTION: The primary limitation is the study's retrospective design, which introduces risks of selection and confusion bias, although multivariable analysis was employed to mitigate these issues. WIDER IMPLICATIONS OF THE FINDINGS: Managing high serum E2 levels on the day of the FBT may enhance ART outcomes. Future research should aim to define optimal E2 thresholds for HRT-FBT cycles and develop personalized treatment protocols that account for individual patient variability. STUDY FUNDING/COMPETING INTEREST(S): No funding was received. The authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Maignien C, Jobin T, Bourdon M, et al. High serum estradiol levels on the day of frozen blastocyst transfer are associated with increased early miscarriage rates in artificial cycles using transdermal estrogens. Hum Reprod. 2025. PMID: 40052481. doi:10.1093/humrep/deaf037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。